Advance Online
A black girl running outside with a wooden toy plane in her hand.
Advance Online

FDA Approves STELARA® For Use in Pediatric Patients With PsA

An expanded approval gives a new treatment option to children with psoriatic disease.

On August 1, 2022, the U.S. Food and Drug Administration (FDA) approved STELARA® (ustekinumab) for the treatment of pediatric patients ages 6 years and older, who have active psoriatic arthritis (PsA). STELARA® is the first and only biologic that targets interleukin (IL)-12 and IL-23, which are cytokines thought to be involved in tempering an overactive inflammatory response in some autoimmune and immune-mediated diseases. [1]

Using pharmacokinetic (PK) data, this approval is based on the established efficacy and existing safety profile of STELARA® from the PSTELLAR, CADMUS, and CADMUS Jr Phase 3 studies (examined adult and pediatric psoriasis (PsO)) and PSUMMIT I and II (examined active adult PsA). A statement from Janssen Pharmaceutical Companies of Johnson & Johnson said, “An analysis of the data demonstrated that PK exposure of STELARA® in these pediatric PsO patients with active PsA was consistent with that of Phase 3 clinical trials of STELARA® in pediatric PsO patients without active PsA, as well as with adult patients with moderate to severe plaque PsO or adult patients with active PsA, while data on common efficacy endpoints were similar in these pediatric PsO patients with active PsA.” [1]

PsA is estimated to affect between 5% and 8% of children and adolescents with chronic inflammatory arthritis. [1]

Stay Informed

Want to be alerted to the latest treatment options for psoriatic disease? Sign up to receive announcements by email.

Sign up now

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.